KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $281000.0.

  • Xenon Pharmaceuticals' Capital Expenditures fell 5237.29% to $281000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 4666.67%. This contributed to the annual value of $3.1 million for FY2024, which is 4525.55% down from last year.
  • Xenon Pharmaceuticals' Capital Expenditures amounted to $281000.0 in Q3 2025, which was down 5237.29% from $157000.0 recorded in Q2 2025.
  • Xenon Pharmaceuticals' Capital Expenditures' 5-year high stood at $2.2 million during Q1 2023, with a 5-year trough of $43000.0 in Q1 2025.
  • For the 5-year period, Xenon Pharmaceuticals' Capital Expenditures averaged around $743000.0, with its median value being $514000.0 (2021).
  • The largest annual percentage gain for Xenon Pharmaceuticals' Capital Expenditures in the last 5 years was 94056.6% (2023), contrasted with its biggest fall of 9554.79% (2023).
  • Over the past 5 years, Xenon Pharmaceuticals' Capital Expenditures (Quarter) stood at $514000.0 in 2021, then surged by 240.86% to $1.8 million in 2022, then plummeted by 95.55% to $78000.0 in 2023, then surged by 903.85% to $783000.0 in 2024, then crashed by 64.11% to $281000.0 in 2025.
  • Its Capital Expenditures was $281000.0 in Q3 2025, compared to $157000.0 in Q2 2025 and $43000.0 in Q1 2025.